Severity of COVID-19 and Treatment Strategy for Patient With Diabetes
Coronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and hig...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.602735/full |
| _version_ | 1818608693255602176 |
|---|---|
| author | Shi Jin Weina Hu |
| author_facet | Shi Jin Weina Hu |
| author_sort | Shi Jin |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and higher mortality rates in patients, especially those who are with comorbidities, including high blood pressure, cardiovascular disease, obesity, and diabetes, increases the concern over the consequences of this pandemic. However, initial reports do not clearly describe whether diabetes itself or associated comorbidities or treatment strategies contribute to the severe prognosis of COVID-19 infections. Various clinical trials are being conducted on glucose-lowering agents but to date, there is no standard treatment protocol approved for COVID-19 cases with pre-existing diabetes. This review is aimed to decipher the potential risk factors of COVID-19 involved from existing evidence. Identification of a novel therapeutic strategy could be beneficial for combating SARS-CoV-2, which might be dreadful to debilitating people who have diabetes. |
| first_indexed | 2024-12-16T14:46:42Z |
| format | Article |
| id | doaj.art-9dafda7808944bc0aa08fc189a91ef5a |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-16T14:46:42Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-9dafda7808944bc0aa08fc189a91ef5a2022-12-21T22:27:45ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-04-011210.3389/fendo.2021.602735602735Severity of COVID-19 and Treatment Strategy for Patient With DiabetesShi Jin0Weina Hu1Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, ChinaDepartment of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, ChinaCoronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and higher mortality rates in patients, especially those who are with comorbidities, including high blood pressure, cardiovascular disease, obesity, and diabetes, increases the concern over the consequences of this pandemic. However, initial reports do not clearly describe whether diabetes itself or associated comorbidities or treatment strategies contribute to the severe prognosis of COVID-19 infections. Various clinical trials are being conducted on glucose-lowering agents but to date, there is no standard treatment protocol approved for COVID-19 cases with pre-existing diabetes. This review is aimed to decipher the potential risk factors of COVID-19 involved from existing evidence. Identification of a novel therapeutic strategy could be beneficial for combating SARS-CoV-2, which might be dreadful to debilitating people who have diabetes.https://www.frontiersin.org/articles/10.3389/fendo.2021.602735/fullDiabetes mellitusCOVID-19SARS-CoV-2cytokine stormglycemic control |
| spellingShingle | Shi Jin Weina Hu Severity of COVID-19 and Treatment Strategy for Patient With Diabetes Frontiers in Endocrinology Diabetes mellitus COVID-19 SARS-CoV-2 cytokine storm glycemic control |
| title | Severity of COVID-19 and Treatment Strategy for Patient With Diabetes |
| title_full | Severity of COVID-19 and Treatment Strategy for Patient With Diabetes |
| title_fullStr | Severity of COVID-19 and Treatment Strategy for Patient With Diabetes |
| title_full_unstemmed | Severity of COVID-19 and Treatment Strategy for Patient With Diabetes |
| title_short | Severity of COVID-19 and Treatment Strategy for Patient With Diabetes |
| title_sort | severity of covid 19 and treatment strategy for patient with diabetes |
| topic | Diabetes mellitus COVID-19 SARS-CoV-2 cytokine storm glycemic control |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.602735/full |
| work_keys_str_mv | AT shijin severityofcovid19andtreatmentstrategyforpatientwithdiabetes AT weinahu severityofcovid19andtreatmentstrategyforpatientwithdiabetes |